AMI-193

Research use only, not for human use.

AMI-193 is an effective and selective antagonist of 5-HT2 and D2 receptor with Kis of 2, 3, 50, 2530, and 4300 nM for 5-HT2, D2 Receptor, 5-HT1A, D1 Receptor, and 5-HT1C Receptor.

AMI-193 is an effective and selective antagonist of 5-HT2 and D2 receptor with Kis of 2, 3, 50, 2530, and 4300 nM for 5-HT2, D2 Receptor, 5-HT1A, D1 Receptor, and 5-HT1C Receptor. AMI-193 shows antipsychotic activity.(In Vivo):In adult male squirrel monkeys, AMI-193 (0.003 and 0.01 mg/kg; i.m.) decreases the response rate under a fixed-interval (FI) schedule of stimulus termination in a dose-dependent manner and under a second-order schedule of i.v. self-administration of cocaine (0.1 mg/infusion). AMI-193 (0.003 and 0.01 mg/kg; i.m.) attenuates the discriminative-stimulus effects of cocaine.

Spiramide retains affinity for 5-HT1A sites (Ki=50 nM) and also binds at dopamine D2 sites (Ki=3 nM), but possesses low affinity for dopamine D1 sites (Ki=2530 nM).

AMI-193 (0.003-0.01 mg/kg; i.m.) dose-dependently decreases response rate in monkeys under a fixed-interval (FI) schedule of stimulus termination.AMI-193 (0.003-0.01 mg/kg; i.m.) attenuates the discriminative-stimulus effects of cocaine in drug-discrimination experiments.AMI-193 (0.003-0.01 mg/kg; i.m.) reduces response rate under a second-order schedule of i.v. self-administration of cocaine (0.1 mg/infusion). Animal Model:Adult male squirrel monkeys (850-1300 g) Dosage:0.003, 0.01 mg/kg Administration:I.m. on Tuesday, Wednesday, and Thursday the following week Result:Decreased the response rate.The rate-decreasing effects were reversed by cocaine.

Spiramide | Espiramida

GPCR/G Protein

Dopamine Receptor

——

——

——

510-74-7

383.46

C22H26FN3O2

>98% (HPLC)

In Vitro:?DMSO : 20 mg/mL (52.16 mM)

O=C1NCN(C=2C=CC=CC2)C13CCN(CCCOC4=CC=C(F)C=C4)CC3

——

(-20℃)

With Ice Pack

≥ 2 years